20 June 2013
Keywords: preladenant, reduces, off-time, ph, ii, pd, trial
Article | 08 December 2008
US drug major Schering-Plough's preladenant met the primary endpoint in a Phase II dose-finding trial in patients suffering from
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 December 2008
1 December 2008
19 June 2013
© 2013 thepharmaletter.com